CASP1 and type 2 diabetes mellitus: Compared with T2D mice treated with PBS, FreemCas9/gNLRP3 or CLANmCas9/gNC, IL-1β secretion and caspase-1 cleavage in WAT was dose-dependently reduced by CLAMmCas9/gNLRP3 treatment (Fig. 7e).